1RAKHA EA, EI-SAYED M E, GREEN A R. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1):25.
2RODRIGUEZ PINILI.A S M, SARRIO D, HONRADO E, et al. Prognostic significance of basal-like phenotype and fasein expression in node-negative invasive breast carcinomas[J]. Clin Cancer Res, 2006,12:1533.
3MINN A J, GUPTA G P, SIEGEL P M, et al. Genes that mediate breast cancer metastasis to lung[J]. Nature, 2005, 436(7050) :518-524.
4IRVIN W J J X, CAREY L A. What is triple-negative breast cancer[J]? Eur J Cancer, 2008,44(18):2799-2805.
5YOUNG S R, ROBERT T P, TALIA D, et al. The prevalence of BRCA1 mutations among young women with triple- negative breast cancer[J]. BMC Cancer, 2009, 9:86.
6KREIKE B, VAN KOUWENHOVE M, HORLINGS H, et al. Gene expression profiling and histopathological characte- rization of triple negative/basal-like breast carcinomas[J]. Breast Cancer Res, 2007,9:R65.
7TAN A R, SWAIN S M. Therapeutic strategies for triplenegative breast cancer[J].Cancer J , 2008,14 (6):343-351.
8KEAM B, IM S A, KIM H J, et al. Prognostic impact of clinico pathologic parameters in stage U/UI breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxi cal features of the triple negative breast cancer[J]. BMC Cancer. 2007,7:203.
9LIEDTKE C, MAZOUNI C, HESS K R, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. Journal of Clinical Oncology, 2008,26:1275-1281.
10CHANG H R, SLAMON D, GORNBEIN J A, et al. Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)[J].J Clin Oncol, 2008,26(Suppl): 604.
3HENDERSON C, BERRY D A, DEMETRI G D, et al. Improved outcome from adding sequential paclitaxel but not from escalating doxorubicin does in an adjuvant chemotherapy regimen for patients with node-positive primary breatst cancer[J]. Clin Oncol , 2003,21:976-983.
1RAKHA E A,EL-SAYED M E,GREEN A R,et al.Prognostic markers in triple negative breast cancer[J].Cancer,2007,109:25-32.
2REIS-FILHO J S,MILANEZI F,STEELE D,et al.Metaplastic breast carcinomas are basal-like tumours[J].Histopathology,2006,49(1):10.
3BAUER K R,BROWN M,CRESS R D,et al.Descriptive analysis of estrogen receptor (ER)-negative,progesterone receptor(PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype:a populationbased study from the California Cancer Registry[J].Cancer,2007,109:1721-1728.
4GOLDHIRSCH A,WOOD W C,GELBER R D,et al.Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer[J].Ann Oncol,2007,18:1133-1144.
5LIVASY C A,KARACA G,NANDA R,et al.Phenotypic evaluation of the basal-like subtype to invasive breast carcinoma[J].Mod Pathol,2006,19:264-271.
6RAKHA E A,EL-SAYED M E,GREEN A R,et al.Prognostic markers in triple negative breast cancer[J].Cancer,2007,109(1):25.
7DENT R,TMDEAU M,PRITCHARD K I,et al.Triplenegative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434.
8LIEDTKE C,MAZOUNI C,HESS K R,et al.Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer[J].Clin Oncol,2008,26 (8):1275-1281.
9LIEDTKE C,MAZOUNI C,HESS K R,et al.Response and outcome after neoadjuvant therapy in patients with triple negative vs.non-TN breast cancer[J].J Clin Oncol,2008,26(1):1275-1281.
